M&A Deal Summary

Bausch Health Acquires Salix Pharmaceuticals

On February 22, 2015, Bausch Health acquired life science company Salix Pharmaceuticals for 14.5B USD

Acquisition Highlights
  • This is Bausch Health’s 17th transaction in the Life Science sector.
  • This is Bausch Health’s largest (disclosed) transaction.
  • This is Bausch Health’s 16th transaction in the United States.
  • This is Bausch Health’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2015-02-22
Target Salix Pharmaceuticals
Sector Life Science
Buyer(s) Bausch Health
Deal Type Add-on Acquisition
Deal Value 14.5B USD
Advisor(s) Centerview Partners
J.P. Morgan Securities (Financial)
Cadwalader, Wickersham & Taft (Legal)

Target

Salix Pharmaceuticals

Raleigh, North Carolina, United States
Salix Pharmaceuticals Ltd. is a developer and marketer of prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through Salix's gastroenterology specialty sales and marketing team.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bausch Health

Laval, Quebec, Canada
Category Company
Sector Life Science
Employees20,270
Revenue 8.8B USD (2023)
DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.

DEAL STATS #
Overall 28 of 35
Sector (Life Science) 17 of 21
Type (Add-on Acquisition) 20 of 25
State (North Carolina) 1 of 2
Country (United States) 16 of 22
Year (2015) 1 of 6
Size (of disclosed) 1 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-11-17 NicOx

Warren Township, New Jersey, United States

NicOx, Inc. distributes nitric oxide (NO)-donating drug.

Buy $20M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-23 Dendreon Pharmaceuticals  

Seattle, Washington, United States

Dendreon Pharmaceuticals, Inc. is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

Buy $400M
Mergr

Product

Company

Legal